Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study.
Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study.
复制标题
在患有 ADHD、行为/对立违抗障碍和攻击性的耐哌甲酯治疗的青少年中添加喹硫平：一项前瞻性、开放标签研究。
DOI：
--
复制
发表时间：
2007
影响因子：
1.9
通讯作者：
D. Dunn
中科院分区：
文献类型：
--
作者：
W. Kronenberger;Ann L. Giauque;Deborah Lafata;B. Bohnstedt;Laura E Maxey;D. Dunn
客观化
这项研究调查了非典型抗精神病药物奎硫平加入正在进行的OROS哌甲酯治疗中的安全性和有效性，以治疗对单一哌酸甲酯治疗不完全有效的患有ADHD和严重攻击的青少年。
方法
12-16岁的参与者参加了一项前瞻性的开放试验，试验包括3周的OROS哌酸甲酯单一治疗，滴定到每天54毫克，然后是9周的奎硫平和哌酸甲酯的联合治疗。在30名参与者中，有24人未能达到单独使用哌醋甲酯治疗后显著改善的标准(临床总体改善-严重程度[CGI-S]和对人和财产的攻击评定量表评分1或2，多动症评定量表：调查者接受治疗并评分[ADHD-RS-I]评分低于基线分数的50%)，并接受综合治疗。
结果
研究人员和父母对ADHD症状、攻击性和全球功能的评分在单独治疗和联合治疗期间显著改善。在联合治疗结束时，42%的样本符合临床显著改善的所有标准，79%的样本表现出轻微的攻击性。据报道，大约一半的病例出现了轻度和短暂的镇静。联合治疗期间体重增加(1.2公斤)抵消了哌甲酸甲酯治疗期间的体重减轻(0.9公斤)。
结论
奎硫平与哌酸甲酯联用可以有效地减少对单独服用54毫克/天的哌酸甲酯的患者的ADHD和攻击性(根据CGI-S、RAAPP和ADHD-RS-I标准，有显著改善)。
OBJECTIVE
This study investigated the safety and efficacy of adding the atypical antipsychotic quetiapine to ongoing OROS methylphenidate treatment for adolescents with comorbid ADHD and severe aggression that were incompletely responsive to methylphenidate monotherapy.
METHOD
Participants aged 12-16 years were enrolled in a prospective, open-label trial consisting of 3 weeks of OROS methylphenidate monotherapy titrated to 54 mg/day, followed by 9 weeks of combination treatment with quetiapine and methylphenidate. Twenty-four out of thirty participants failed to meet criteria for significant improvement (Clinical Global Improvement-Severity [CGI-S] and Rating of Aggression Against People and Property [RAAPP] scale scores of 1 or 2 and ADHD-Rating Scale: Investigator Administered and Scored [ADHD-RS-I] score less than 50% of baseline score) with methylphenidate treatment alone and received combined treatment.
RESULTS
Investigator and parent ratings of ADHD symptoms, aggression, and global functioning improved significantly during both methylphenidate monotherapy treatment and during combined methylphenidate-quetiapine treatment. At the conclusion of combined treatment, 42% of the sample met all criteria for clinically significant improvement and 79% showed minimal aggression. Mild and transient sedation was reported by about half the cases. Weight loss (0.9 kg) during methylphenidate treatment was offset by weight gain (1.2 kg) during combination treatment.
CONCLUSION
Quetiapine addition to methylphenidate was effective in reducing ADHD and aggression in individuals who did not respond sufficiently (based on CGI-S, RAAPP, and ADHD-RS-I criteria for significant improvement) to OROS methylphenidate alone at a 54-mg/day dose.
登录
查看更多内容
针对攻击性青少年使用抗精神病药物的治疗建议（TRAAY）。
DOI：
10.1097/00004583-200302000-00007
发表时间：
2003
影响因子：
13.3
作者：
Schur,SarahB;Sikich,Lin;Findling,RobertL;Malone,RichardP;Crismon,MLynn;Derivan,Albert;MacintyreIi,JamesC;Pappadopulos,Elizabeth;Greenhill,Laurence;Schooler,Nina;VanOrden,Kimberly;Jensen,PeterS
通讯作者：
Jensen,PeterS
DOI：
10.1097/00004583-200102000-00012
发表时间：
2001-02-01
影响因子：
13.3
作者：
Greenhill, LL;Swanson, JM;Wigal, T
通讯作者：
Wigal, T
喹硫平治疗广泛性发育障碍的回顾性分析。
DOI：
10.4088/jcp.v65n1115
发表时间：
2004
期刊：
The Journal of clinical psychiatry
影响因子：
--
作者：
Corson,AdamH;Barkenbus,JohnE;Posey,DavidJ;Stigler,KimberlyA;McDougle,ChristopherJ
通讯作者：
McDougle,ChristopherJ
哌醋甲酯治疗患有或不患有注意缺陷多动障碍的品行障碍的临床疗效。
影响因子：
--
作者：
Klein,RG;Abikoff,H;Klass,E;Ganeles,D;Seese,LM;Pollack,S
通讯作者：
Pollack,S